Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SEEVO -1.28%57 EV-to-OCF is -5.11 as of Aug. 21, 2026. GuruFocus rates EVO with a GF Score™ of 57/100 and a GF Value™ of $3.61 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Evotec SE ranks better than 76.92% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Evotec SE's Enterprise Value is $678.6 Mil.
Evotec SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-132.8 Mil. Therefore, Evotec SE's EV-to-OCF for today is -5.11.
The historical rank and industry rank for Evotec SE's EV-to-OCF or its related term are showing as below:
EVO'
s EV-to-OCF Range Over the Past 10 Years
Min: -260.68 Med: 30.91 Max: 785.36
Current: -5.11
During the past 13 years, the highest EV-to-OCF of Evotec SE was 785.36. The lowest was -260.68. And the median was 30.91.
EVO's EV-to-OCF is ranked better than 76.92% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 10.52
vs EVO: -5.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Evotec SE's share price for today is $1.935.
Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.639.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Evotec SE EV-to-OCF Related Terms
Evotec SE EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Evotec SE's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Evotec SE's EV-to-OCF falls into.
Evotec SE's current Enterprise Value is $678.6 Mil.
Evotec SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-132.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVO) has a EV-to-OCF of -5.11 as of Aug. 21, 2026. According to the industry distribution chart, Evotec SE ranks #232 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Evotec SE's EV-to-OCF too high?
Evotec SE's current EV-to-OCF is -5.11. Based on the distribution chart, Evotec SE ranks #232 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evotec SE has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #232 out of 1005 companies for EV-to-OCF. This places Evotec SE in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.52, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current EV-to-OCF is -5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.61, compared to a current price of $1.94 — trading 46.4% below its estimated fair value. The current EV-to-OCF is -5.11. Evotec SE's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Evotec SE (EVO), the current EV-to-OCF is -5.11 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $1.94 is trading 46.4% below its estimated GF Value™ of $3.61.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
EV-to-OCF: -5.11
GF Value™: $3.61 vs. price of $1.94 (46.4% below fair value)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
57GF Score
Get the complete analysis for EVO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
